Activity of pyocin S2 against Pseudomonas aeruginosa biofilms

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 3, 2012, Pages 1599-1601

  Smith, Karen ^a   Martin, Laura ^a   Rinaldi, Angela ^a   Rajendran, Ranjith ^a   Ramage, Gordon ^a   Walker, Daniel ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PYOCIN; PYOCIN S2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BACTERIUM ISOLATE; BIOFILM; CATERPILLAR; CONTROLLED STUDY; GALLERIA MELLONELLA; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION;

ANIMALS; ANTI-BACTERIAL AGENTS; AZTREONAM; BIOFILMS; CHILD; CYSTIC FIBROSIS; HUMANS; LARVA; LUNG; MICROSCOPY, ELECTRON, SCANNING; MOTHS; PSEUDOMONAS AERUGINOSA; PYOCINS; SPUTUM; TOBRAMYCIN;

EID: 84863412234     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05714-11     Document Type: Article

References (14)

1. Ceri H, et al. 2001. The MBEC Assay System: multiple equivalent biofilms for antibiotic and biocide susceptibility testing. Methods Enzymol. 337:377-385. (Pubitemid 32691309)
2. Denayer S, Matthijs S, Cornelis P. 2007. Pyocin S2 (Sa) kills Pseudomonas aeruginosa strains via the FpvA type I ferripyoverdine receptor. J. Bacteriol. 189:7663-7668. (Pubitemid 350035076)
3. Reference deleted.
4. Flamm RK, et al. 2004. Factors associated with relative rates of antibiotic resistance in Pseudomonas aeruginosa isolates tested in clinical laboratories in the United States from 1999 to 2002. Antimicrob. Agents Chemother. 48:2431-2436.
5. Harrison F, Browning LE, Vos M, Buckling A. 2006. Cooperation and virulence in acute Pseudomonas aeruginosa infections. BMC Biol. 4:21.
6. Kleanthous C. 2010. Swimming against the tide: progress and challenges in our understanding of colicin translocation. Nat. Rev. Microbiol. 8:843-848.
7. Loftus SR, et al. 2006. Competitive recruitment of the periplasmic translocation portal TolB by a natively disordered domain of colicin E9. Proc. Natl. Acad. Sci. U. S. A. 103:12353-12358. (Pubitemid 44267263)
8. Lyczak JB, Cannon CL, Pier GB. 2002. Lung infections associated with cystic fibrosis. Clin. Microbiol. Rev. 15:194-222. (Pubitemid 34303763)
9. Mah TF, et al. 2003. A genetic basis for Pseudomonas aeruginosa biofilm antibiotic resistance. Nature 426:306-310.
10. Miyata S, Casey M, Frank DW, Ausubel FM, Drenkard E. 2003. Use of the Galleria mellonella caterpillar as a model host to study the role of the type III secretion system in Pseudomonas aeruginosa pathogenesis. Infect. Immun. 71:2404-2413. (Pubitemid 36519851)
11. Murray TS, Egan M, Kazmierczak BI. 2007. Pseudomonas aeruginosa chronic colonization in cystic fibrosis patients. Curr. Opin. Pediatr. 19:83-88. (Pubitemid 46114762)
12. O'Sullivan BP, Yasothan U, Kirkpatrick P. 2010. Inhaled aztreonam. Nat. Rev. Drug Discov. 9:357-358.
13. Parret AH, De Mot R. 2002. Bacteria killing their own kind: novel bacteriocins of Pseudomonas and other γ-proteobacteria. Trends Microbiol. 10:107-112. (Pubitemid 34178316)
14. Souli M, Galani I, Giamarellou H. 2008. Emergence of extensively drugresistant and pandrug-resistant Gram-negative bacilli in Europe. Euro Surveill. 13(47):pii=19045.